HomeSolutionsPricingAbout UsContact
🇺🇸English
Try Now
Home/Stocks/CUE
CUE

CUE

USD

Cue Biopharma Inc. Common Stock

$0.639+0.011 (1.752%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$0.628

High

$0.660

Low

$0.620

Volume

0.10M

Company Fundamentals

Market Cap

48.1M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.16M

Exchange

NCM

Currency

USD

52-Week Range

Low $0.45Current $0.639High $1.989

Related News

GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

View more
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

View more
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

View more
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

View more
Cue Biopharma Announces Proposed Public Offering
GlobeNewswire

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel,

View more
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Related Stocks

CLDI

CLDI

Calidi Biotherapeutics Inc.

NASDAQ
Biotechnology: ...
INAQ

INAQ

Insight Acquisition Corp.

NASDAQ
Blank Checks
HYMC

HYMC

Hycroft Mining Holding Corporation

NASDAQ
Precious Metals
INTT

INTT

inTest Corporation

NASDAQ
Electrical Prod...
AGNCP

AGNCP

AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 6.125% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

NASDAQ
Real Estate Inv...

Stay Updated

Set price alerts, get AI analysis updates and real-time market news.